Indeed, we found that treatment of ~3-week-old c1LysMcrec2−/−and c1LysMcrex−/−c2−/− mice with neutralizing TNF antibody reduced clinical manifestations including, clinical arthritis and neutrophil MPO activity in limbs (Fig. 8j,k). The gene discussed is MPO; the disease is arthritic joint disease.